Beyond Obesity
sleep apnea, liver disease, cardiovascular outcomes, and the expanding clinical portfolio
An Expanding Indication Map
Tirzepatide's clinical program extends well beyond diabetes and weight management. Eli Lilly is running or has completed trials in obstructive sleep apnea (SURMOUNT-OSA), metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), heart failure with preserved ejection fraction, and cardiovascular outcomes (SURPASS-CVOT). Some of these results have already led to new approvals. This unit covers the evidence for each indication, what's been approved, and what remains in the pipeline.
Indications Timeline
Track tirzepatide's expanding clinical portfolio from diabetes approval through emerging indications.